CCL2 and mucopolysaccharidosis type 3A: Following the observance of increased MCP-1, in both acute and chronic low poly(I:C) dosing, as well as the increased production of splenic monocytes and macrophages in the chronic disease setting of MPS IIIA, we sought to determine if this translated into long-term elevation of microglial cell engraftment and activation in the brain.